4687-08-5

Upstream product

• 4925-90-0 methyl 4-chloro-α-(3-trifluoromethylphenoxy)phenylacetate 
• 93961-29-6 methyl 2-(4-chlorophenyl)-2-diazoacetate 
• 52449-43-1 (4-chloro-phenyl)-acetic acid methyl ester 
• 186025-92-3 methyl 4-chloro-α-(methanesulfonyloxy)phenylacetate 
• 32174-34-8 methyl 4-chloromandelate 
• 7138-34-3 p-chloromandelic acid 
• 401-81-0 m-trifluoromethylphenyl iodide 
• 24136-23-0 2-acetamidoethyl (3-trifluoromethylphenoxy)(4-chlorophenyl)acetate 

Downstream Products

• 24091-95-0 (3-trifluoromethylphenoxy)-(4-chlorophenyl)acetyl chloride 
• 23953-39-1 (2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetic acid 

Relevant academic research and scientific papers

Catalytic O-H bond insertion reactions using surface modified sewage sludge as a catalyst

Developing a greener, sustainable catalyst is a very important but challenging task in organic synthesis. Herein, for the first time, we choose more economical and greener surface modified sewage sludge-derived carbonaceous materials (SW) treated by perch

Preparation method of optically-active R-4-chloro-alpha-(3-trifluoromethyl phenoxy)phenylacetic acid

The invention discloses a preparation method of R-4-chloro-alpha-(3-trifluoromethyl phenoxy)phenylacetic acid, belongs to the field of organic synthesis, and particularly provides a preparation methodof optically-active R-4-chloro-alpha-(3-trifluoromethyl

On the metabolically active form of metaglidasen: Improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles

Metaglidasen is a fibrate-like drug reported as a selective modulator of peroxisome proliferator-activated receptor γ (PPARγ), able to lower plasma glucose levels in the absence of the side effects typically observed with thiazolidinedione antidiabetic agents in current use. Herein we report an improved synthesis of metaglidasen's metabolically active form halofenic acid (R)-2 and that of its enantiomer (S)-2. The activity of the two stereoisomers was carefully examined on PPARα and PPARγ subtypes. As expected, both showed partial agonist activity toward PPARγ; the investigation of PPARα activity, however, led to unexpected results. In particular, (S)-2 was found to act as a partial agonist, whereas (R)-2 behaved as an antagonist. X-ray crystallographic studies with PPARγ were carried out to gain more insight on the molecular-level interactions and to propose a binding mode. Given the adverse effects provoked by fibrate drugs on skeletal muscle function, we also investigated the capacity of (R)-2 and (S)-2 to block conductance of the skeletal muscle membrane chloride channel. The results showed a more beneficial profile for (R)-2, the activity of which on skeletal muscle function, however, should not be overlooked in the ongoing clinical trials studying its long-term effects.

Resolution of alpha-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines

The present invention provides a methods and compounds for producing an enantiomerically enriched α-(phenoxy)phenylacetic acid compound of the formula: from a mixture of its enantiomers, where R1 is alkyl or haloalkyl and X is halide.

METHODS FOR AVOIDING EDEMA IN THE TREATMENT OR PREVENTION OF PPARγ-RESPONSIVE DISEASES, INCLUDING CANCER

Compounds, compositions, and methods of avoiding edema while treating or preventing PPARγ-mediated diseases, including cancer, using derivatives and prodrugs are provided.

RESOLUTION OF α-(PHENOXY)PHENYLACETIC ACID DERIVATIVES

The present invention provides a method for producing an enantiomerically enriched alpha-(phenoxy)phenylacetic acid compound of the formula (I): from its enantiomeric mixture, where R1 is alkyl or haloalkyl and X is halide.

Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia

The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.

Use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia

The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. It further provides (?) (3-trihalomet

Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia

The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.

Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia

The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.